First-Line Treatment of ALK-Positive NSCLC
Non-small cell lung cancer (NSCLC) patients with rearrangements in the anaplastic lymphocyte kinase (ALK) gene are highly sensitive to ALK tyrosine kinase inhibitors (TKIs) like alectinib. Here, the case of a 77-year-old male patient with newly diagnosed metastatic ALK-positive NSCLC treated with al...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2019-11-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Subjects: | |
| Online Access: | https://onco-hema.healthbooktimes.org/article/24407-first-line-treatment-of-_alk_-positive-nsclc |